Hepatic vitamin D 25-hydroxylase: inhibition by bile duct ligation or bile salts.
Bone disease and low serum levels of 25-hydroxyvitamin D are prevalent in cholestatic syndromes such as primary biliary cirrhosis and biliary atresia. Defective hydroxylation, along with malabsorption of vitamin D, could be a factor in 25-hydroxyvitamin D depletion. To assess hepatic hydroxylation during experimental cholestasis, we studied vitamin D 25-hydroxylase activity in liver homogenates of rats after 7, 14, and 21 days of bile duct ligation. We have also studied the effects of bile acids on this enzyme in vitro. Hepatic 25-hydroxylation was depressed after 7 days ligation in only 1 of 4 animals, but by 14 days, all animals showed a marked reduction with a mean decrease of 64% in specific activity. Total liver enzyme activity was reduced by 43% at 14 days. In the ligated animals, liver histology showed progressive bile stasis, focal necrosis, bile ductular proliferation, periductular and periportal inflammation, and fibrosis. Addition of bile acids to the in vitro assay in concentrations approximating those found in cholestasis produced marked inhibition of vitamin D 25-hydroxylase activity.
D015652:25-Hydroxyvitamin D 2; D000818:Animals; D001647:Bile Acids and Salts / Q000494:pharmacology; D053493:Cholestanetriol 26-Monooxygenase; D002779:Cholestasis / Q000378:metabolism; D003135:Common Bile Duct / Q000601:surgery; D004872:Ergocalciferols / Q000031:analogs & derivatives* / Q000378:metabolism; D006900:Hydroxylation; D008026:Ligation; D008099:Liver / Q000201:enzymology* / Q000473:pathology; D051381:Rats; D013250:Steroid Hydroxylases / Q000378:metabolism*
D001647:Bile Acids and Salts; D004872:Ergocalciferols; D015652:25-Hydroxyvitamin D 2; D013250:Steroid Hydroxylases; D053493:Cholestanetriol 26-Monooxygenase